Off Script: A Pharma Manufacturing Podcast Pharma Manufacturing

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — GSK antibiotic hits phase 3 goals in gonorrheaThe bad — Genentech ends $3B Adaptimmune T-cell collabThe ugly — Par Pharmaceutical recalls Treprostinil injection for potential contamination

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — BMS schizophrenia drug shines in phase 3 trialThe bad — Novartis to axe 680 jobsThe ugly — Lilly compounding suit dismissed

Politics, whether we like them or not, weigh heavy on manufacturing’s future.
In case you haven’t heard, it is an election year! Which means, global trade, regulations, immigration, national security and taxation will all be part of the national discourse, and all of those topics touch on manufacturing in one way or another.
During this podcast, we will share a discussion courtesy of our sister brand, IndustryWeek, as part of their livestream program, Production Pulse. The broadcast features insights from Pharma Manufacturing’s chief content director Karen Langhauser as well as from editors on Machine Design and Food Processing.

Editor's Review: Week of April 1Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Basilea Pharmaceutica receives FDA approval for its IV antibioticThe bad — Verve Therapeutics halts gene editing trial, againThe ugly — Amylyx removes ALS treatment from market

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — FDA approves Akebia Therapeutics' Vafseo anemia drugThe bad — Bristol Myers Squibb's Crohn's disease drug disappoints The ugly — FDA rejects Regeneron Pharmaceuticals lymphoma treatment 

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Orchard gene therapy wins first FDA nod for rare pediatric diseaseThe bad — Abiomed recalls heart pump instructions due to perforation risks The ugly — J&J files lawsuit against a former employee for allegedly taking over 1,000 files to Pfizer